BioSpace News Archive

Poseida Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for P-MUC1C-ALLO1, the Company’s allogeneic CAR-T product candidate targeting multiple solid tumor indications.

Virpax ® Pharmaceuticals, Inc. signed a clinical trial agreement with Altasciences Company, Inc. for a First in Human study investigating Epoladerm™ for pain associated with osteoarthritis of the knee.

AtriCure to Participate in the 40th Annual J.P. Morgan Healthcare Conference,

Live cell imaging has attracted the interest of biomedical researchers. The expanding application of cell imagers in life sciences industries is a key evolutionary trend in the cell imagers market.

Hemogenyx Pharmaceuticals will leverage WuXi Advanced Therapies’ plasmid and lentiviral vector manufacturing platforms, including integrated testing, to accelerate HEMO-CAR-T programme for acute myeloid leukaemia toward phase I clinical trials.

XNK Therapeutics AB (“XNK”) today announced the appointment of Dr. Gunilla Enblad, Professor of oncology at Uppsala University, and Dr. Rizwan Romee, Associate Professor of Medicine at Harvard Medical School, as scientific advisors.

Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), today announced that top-line data from its Phase 3 REVERSE trial will be delayed from our previous guidance of near the end of the year and is now expected in the first quarter of 2022.

Providence Therapeutics and Everest Medicines announced today that their COVID-19 vaccine, PTX-COVID19-B, has been recommended by an independent advisory group to be part of the Solidarity Trial Vaccines (“STV”) clinical trial.

Biovo Technologies Ltd., a medical device company focused on devices for Critical Care and Operating Rooms, announced it has signed an agreement with a leading US hospital based in New Jersey, for performing a clinical study of the Cuffix device.

Affera Inc. announced today that the first patient was treated in the recently approved SPHERE PerAF Trial, a U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) pivotal randomized trial, to evaluate the safety and effectiveness of the Affera system and Sphere-9™ catheter for the treatment of Persistent Atrial Fibrillation (Afib).